The Checkup by Singlecare
APRIL 5, 2024
Insurance companies and Medicare prescription drug plans may cover Ozempic when it’s prescribed for Type 2 diabetes, not weight loss, but it depends on the specific plan. The insurance landscape for Ozempic and similar medications is constantly in flux, and it might feel difficult to keep up with the changes.
STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Checkup by Singlecare
FEBRUARY 7, 2023
The rising cost of living in the United States is making it harder to pay for prescription medicines, even among individuals with health insurance. PAPs are programs that help people with no health insurance and those who are underinsured pay for their medications. Here’s how they work. How do patient assistance programs work?
Viseven
JANUARY 13, 2023
So what do exactly HEOR experts do for the pharmaceutical companies and what HEOR-collected data is used for? HEOR collects all reports about health outcomes from patients and physicians and later provides detailed analytics to healthcare providers, clinical outcomes research institutions or pharmaceutical companies.
Omnicell
JANUARY 10, 2023
In a manual for hemophilia treatment centers, the agency states it is concerned that providers would have no reason to participate in 340B if insurers take the benefit of 340B savings from them. Four of the five staffers originally involved in the investigation now work for or lobby for the pharmaceutical industry.
The Checkup by Singlecare
MARCH 7, 2024
Additionally, medical debt can impact anyone, regardless of background or the quality of health insurance coverage. The prevalence of medical debt in the United States Today, more people have health insurance coverage than ever before because of the passage of the Affordable Care Act.
pharmaphorum
AUGUST 31, 2021
Beyond the FDA, other institutions have documented what industry standards should look like in assessing RWD in a regulatory context. Furthermore, ECAs are well-documented in the post-approval setting. Myth 3: RWD is too imperfect to be used to as a comparator arm to a clinical trial.
Expert insights. Personalized for you.
78 
Let's personalize your content